-
CX-4945 (Silmitasertib), a selective, potent and orally bioavailable inhibitor of potent casein kinase II (CK2), is the first small molecule inhibitor of CK2 to progress to human clinical trials. CX-4945 (Silmitasertib)是高活性ATP竞争性CK2抑制剂，对重组型人CK2α的Ki和IC50分别为0.38和1 nM。
More
-
BI-D1870是ATP竞争性S6核糖体抑制剂，对RSK1/2/3/4的IC50分别为31 nM/24 nM/18 nM/15 nM，比对MST2，GSK-3β，MARK3，CK1 和Aurora B的抑制性高10到100倍。
More
-
Tubastatin A盐酸盐是HDAC6选择性抑制剂，IC50为15 nM，比对其它亚型的抑制性高1000倍（相对HDAC8是57倍）。
More
-
Sodium phenylbutyrate (NaPB), a derivative of the short-chain fatty acid butyrate, is a low-potency histone deacetylase inhibitor and originally approved for treatment of UCD. Sodium Phenylbutyrate是一种转录调节因子，通过调控HDAC活性来改变染色质结构从而发挥作用,是组蛋白脱乙酰酶（HDAC）抑制剂，IC50为1-5 uM。
More
-
Pazopanib, an orally available multi-kinase inhibitor of VEGFR, PDGFR, KIT, FGFR, as well as RAF, shows potent activity against a variety of solid tumors. Pazopanib是多重靶点抑制剂，对VEGFR1， VEGFR2，VEGFR3，PDGFR，FGFR，c-Kit 和 c-Fms的IC50分别为10 nM，30 nM，47 nM，84 nM，74 nM，140 nM和146 nM。
More
